Amarin Corp (AMRN) Pressured Early as Vascepa Orange Book Decision Delayed...Again
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Shares of Amarin Corp Plc (Nasdaq: AMRN) are getting hit Tuesday morning following a late-Monday disclosure for Vascepa.
According to the filing, Amarin said it doesn't expect the FDA to include Vascepa in its Orange Book cumulative supplement, expected to be published on September 14th.
Amarin's Vascepa won FDA approval on July 26th.
Shares are down over 5.7 percent ahead of the opening bell Tuesday. For more commentary on the Orange Book, Jefferies issued an update in August.
According to the filing, Amarin said it doesn't expect the FDA to include Vascepa in its Orange Book cumulative supplement, expected to be published on September 14th.
Amarin's Vascepa won FDA approval on July 26th.
Shares are down over 5.7 percent ahead of the opening bell Tuesday. For more commentary on the Orange Book, Jefferies issued an update in August.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Reinstates Amarin Corporation (AMRN) at Underweight
- AC Immune reports early Phase 1 data for NLRP3 inhibitor ACI-19764
- Gossamer Bio raises up to $250M in private placement for PAH drug
Create E-mail Alert Related Categories
FDA, Insiders' BlogRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
